Your browser doesn't support javascript.
loading
Liver Transplantation for Pediatric Hepatocellular Carcinoma: A Systematic Review.
Kakos, Christos D; Ziogas, Ioannis A; Demiri, Charikleia D; Esagian, Stepan M; Economopoulos, Konstantinos P; Moris, Dimitrios; Tsoulfas, Georgios; Alexopoulos, Sophoclis P.
Afiliação
  • Kakos CD; Surgery Working Group, Society of Junior Doctors, 15123 Athens, Greece.
  • Ziogas IA; Surgery Working Group, Society of Junior Doctors, 15123 Athens, Greece.
  • Demiri CD; Department of Surgery, Division of Hepatobiliary Surgery and Liver Transplantation, Vanderbilt University Medical Center, Nashville, TN 37232, USA.
  • Esagian SM; Surgery Working Group, Society of Junior Doctors, 15123 Athens, Greece.
  • Economopoulos KP; 2nd Department of Pediatric Surgery, "Papageorgiou" General Hospital, Aristotle University School of Medicine, 54124 Thessaloniki, Greece.
  • Moris D; Surgery Working Group, Society of Junior Doctors, 15123 Athens, Greece.
  • Tsoulfas G; Surgery Working Group, Society of Junior Doctors, 15123 Athens, Greece.
  • Alexopoulos SP; Department of Surgery, Duke University Medical Center, Durham, NC 27710, USA.
Cancers (Basel) ; 14(5)2022 Mar 02.
Article em En | MEDLINE | ID: mdl-35267604
ABSTRACT
Liver transplantation (LT) is the only potentially curative option for children with unresectable hepatocellular carcinoma (HCC). We performed a systematic review of the MEDLINE, Scopus, Cochrane Library, and Web of Science databases (end-of-search date 31 July 2020). Our outcomes were overall survival (OS) and disease-free survival (DFS). We evaluated the effect of clinically relevant variables on outcomes using the Kaplan-Meier method and log-rank test. Sixty-seven studies reporting on 245 children undergoing LT for HCC were included. DFS data were available for 150 patients and the 1-, 3-, and 5-year DFS rates were 92.3%, 89.1%, and 84.5%, respectively. Sixty of the two hundred and thirty-eight patients (25.2%) died over a mean follow up of 46.8 ± 47.4 months. OS data were available for 222 patients and the 1-, 3-, and 5-year OS rates were 87.9%, 78.8%, and 74.3%, respectively. Although no difference was observed between children transplanted within vs. beyond Milan criteria (p = 0.15), superior OS was observed in children transplanted within vs. beyond UCSF criteria (p = 0.02). LT can yield favorable outcomes for pediatric HCC beyond Milan but not beyond UCSF criteria. Further research is required to determine appropriate LT selection criteria for pediatric HCC.
Palavras-chave

Texto completo: 1 Coleções: 01-internacional Base de dados: MEDLINE Tipo de estudo: Systematic_reviews Idioma: En Ano de publicação: 2022 Tipo de documento: Article

Texto completo: 1 Coleções: 01-internacional Base de dados: MEDLINE Tipo de estudo: Systematic_reviews Idioma: En Ano de publicação: 2022 Tipo de documento: Article